ES2614803T3 - Métodos y composiciones basadas en proteína tipo 2 de la toxina Shiga - Google Patents
Métodos y composiciones basadas en proteína tipo 2 de la toxina Shiga Download PDFInfo
- Publication number
- ES2614803T3 ES2614803T3 ES10733840.2T ES10733840T ES2614803T3 ES 2614803 T3 ES2614803 T3 ES 2614803T3 ES 10733840 T ES10733840 T ES 10733840T ES 2614803 T3 ES2614803 T3 ES 2614803T3
- Authority
- ES
- Spain
- Prior art keywords
- stx2
- seq
- stx1
- toxin
- antibodies
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108090000623 proteins and genes Proteins 0.000 title description 27
- 108010079723 Shiga Toxin Proteins 0.000 title description 15
- 238000000034 method Methods 0.000 title description 15
- 102000004169 proteins and genes Human genes 0.000 title description 10
- 239000000203 mixture Substances 0.000 title description 4
- 108010090763 Shiga Toxin 2 Proteins 0.000 abstract description 68
- 125000003275 alpha amino acid group Chemical group 0.000 abstract description 8
- 108090000765 processed proteins & peptides Proteins 0.000 abstract description 7
- 229920001184 polypeptide Polymers 0.000 abstract description 5
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 5
- 239000003053 toxin Substances 0.000 description 53
- 231100000765 toxin Toxicity 0.000 description 53
- 108700012359 toxins Proteins 0.000 description 53
- 108010091769 Shiga Toxin 1 Proteins 0.000 description 43
- 235000001014 amino acid Nutrition 0.000 description 30
- 150000001413 amino acids Chemical class 0.000 description 30
- 239000013615 primer Substances 0.000 description 22
- 238000006386 neutralization reaction Methods 0.000 description 10
- 241000588724 Escherichia coli Species 0.000 description 9
- 239000013612 plasmid Substances 0.000 description 9
- 235000018102 proteins Nutrition 0.000 description 9
- 239000000427 antigen Substances 0.000 description 8
- 108091007433 antigens Proteins 0.000 description 8
- 102000036639 antigens Human genes 0.000 description 8
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- 238000001262 western blot Methods 0.000 description 6
- 108060003951 Immunoglobulin Proteins 0.000 description 5
- 102000018358 immunoglobulin Human genes 0.000 description 5
- 210000003501 vero cell Anatomy 0.000 description 5
- 101100311322 Escherichia phage 933W stxA2 gene Proteins 0.000 description 4
- 241001529936 Murinae Species 0.000 description 4
- 102100024952 Protein CBFA2T1 Human genes 0.000 description 4
- 102220515626 Pterin-4-alpha-carbinolamine dehydratase 2_Y77S_mutation Human genes 0.000 description 4
- 241000283984 Rodentia Species 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000003053 immunization Effects 0.000 description 4
- 239000002596 immunotoxin Substances 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 3
- 108020004705 Codon Proteins 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 208000032759 Hemolytic-Uremic Syndrome Diseases 0.000 description 3
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 3
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000000474 nursing effect Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 101100367013 Escherichia phage 933W stxB2 gene Proteins 0.000 description 2
- 101000599862 Homo sapiens Intercellular adhesion molecule 3 Proteins 0.000 description 2
- 102100037871 Intercellular adhesion molecule 3 Human genes 0.000 description 2
- 239000006137 Luria-Bertani broth Substances 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 241000607764 Shigella dysenteriae Species 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 2
- 210000003705 ribosome Anatomy 0.000 description 2
- 238000011830 transgenic mouse model Methods 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 description 1
- 208000002109 Argyria Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241001646719 Escherichia coli O157:H7 Species 0.000 description 1
- 102000004961 Furin Human genes 0.000 description 1
- 108090001126 Furin Proteins 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 239000006142 Luria-Bertani Agar Substances 0.000 description 1
- 101100301239 Myxococcus xanthus recA1 gene Proteins 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241000237988 Patellidae Species 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 101100084022 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) lapA gene Proteins 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 108010034949 Thyroglobulin Proteins 0.000 description 1
- 102000009843 Thyroglobulin Human genes 0.000 description 1
- 101710162629 Trypsin inhibitor Proteins 0.000 description 1
- 229940122618 Trypsin inhibitor Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 101150106284 deoR gene Proteins 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 108060003552 hemocyanin Proteins 0.000 description 1
- 208000007475 hemolytic anemia Diseases 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 101150023497 mcrA gene Proteins 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 231100000219 mutagenic Toxicity 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 101150087123 nat gene Proteins 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 238000009520 phase I clinical trial Methods 0.000 description 1
- 101150009573 phoA gene Proteins 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 229940014800 succinic anhydride Drugs 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 230000001732 thrombotic effect Effects 0.000 description 1
- 229960002175 thyroglobulin Drugs 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K14/25—Shigella (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0283—Shigella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0258—Escherichia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
- C07K16/1228—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K16/1232—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia from Escherichia (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
- G01N33/56916—Enterobacteria, e.g. shigella, salmonella, klebsiella, serratia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Biomedical Technology (AREA)
- General Physics & Mathematics (AREA)
- Rheumatology (AREA)
- Biotechnology (AREA)
- Pain & Pain Management (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14689209P | 2009-01-23 | 2009-01-23 | |
| US146892P | 2009-01-23 | ||
| US21008209P | 2009-03-13 | 2009-03-13 | |
| US210082P | 2009-03-13 | ||
| PCT/US2010/021610 WO2010085539A1 (en) | 2009-01-23 | 2010-01-21 | Methods and compositions based on shiga toxin type 2 protein |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2614803T3 true ES2614803T3 (es) | 2017-06-02 |
Family
ID=42356196
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES10733840.2T Active ES2614803T3 (es) | 2009-01-23 | 2010-01-21 | Métodos y composiciones basadas en proteína tipo 2 de la toxina Shiga |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US8969529B2 (enExample) |
| EP (1) | EP2381954B8 (enExample) |
| JP (1) | JP5773886B2 (enExample) |
| KR (1) | KR101832499B1 (enExample) |
| CN (1) | CN102292098A (enExample) |
| AR (1) | AR075047A1 (enExample) |
| AU (1) | AU2010206800B2 (enExample) |
| BR (1) | BRPI1007230B1 (enExample) |
| CA (1) | CA2748873C (enExample) |
| CL (1) | CL2011001769A1 (enExample) |
| ES (1) | ES2614803T3 (enExample) |
| MX (1) | MX2011007866A (enExample) |
| NZ (1) | NZ593926A (enExample) |
| PE (1) | PE20120425A1 (enExample) |
| RU (1) | RU2011126896A (enExample) |
| WO (1) | WO2010085539A1 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1229045A1 (en) * | 2001-02-01 | 2002-08-07 | Institut Curie | Universal carrier for targeting molecules to Gb3 receptor expressing cells |
| MX2008013363A (es) | 2006-04-20 | 2009-03-26 | Jackson H M Found Military Med | Metodos y composiciones basados en la proteina tipo 1 de la toxina shiga. |
| CA2748873C (en) | 2009-01-23 | 2017-09-12 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Methods and compositions based on shiga toxin type 2 protein |
| US9513287B1 (en) * | 2012-09-28 | 2016-12-06 | The United States Of America, As Represented By The Secretary Of Agriculture | High affinity monoclonal antibodies for detection of shiga toxin 2 |
| US9310368B1 (en) * | 2012-09-28 | 2016-04-12 | The United States Of America, As Represented By The Secretary Of Agriculture | High affinity monoclonal antibodies for detection of Shiga toxin 2 (STX2) |
| CN105051067B (zh) * | 2013-03-12 | 2020-04-17 | 分子模板公司 | 用于引起细胞内化的cd20结合免疫毒素及其使用方法 |
| CN103343164B (zh) * | 2013-06-17 | 2016-05-18 | 武汉轻工大学 | 产志贺毒素大肠杆菌多重pcr检测方法、试剂盒及应用 |
| RU2573924C2 (ru) * | 2013-07-11 | 2016-01-27 | Федеральное Государственное Бюджетное Учреждение Науки Институт Молекулярной Биологии Им. В.А. Энгельгардта Российской Академии Наук (Имб Ран) | НЕТОКСИЧНЫЙ РЕКОМБИНАНТНЫЙ ШИГА ТОКСИН 2-ГО ТИПА (Stx2) |
| KR102500408B1 (ko) * | 2014-01-27 | 2023-02-16 | 몰레큘러 템플레이츠, 인코퍼레이션. | 포유류에 적용하기 위한 탈면역된 시가 독소 a 서브유닛 작동체 폴리펩티드 |
| US11142584B2 (en) | 2014-03-11 | 2021-10-12 | Molecular Templates, Inc. | CD20-binding proteins comprising Shiga toxin A subunit effector regions for inducing cellular internalization and methods using same |
| CN113831416A (zh) * | 2014-06-11 | 2021-12-24 | 分子模板公司 | 耐受蛋白酶切割的志贺毒素a亚基效应子多肽和包含其的细胞靶向分子 |
| CN104558167B (zh) * | 2014-12-26 | 2017-12-26 | 江苏省疾病预防控制中心 | 检测i型志贺毒素双抗夹心法酶联免疫试剂盒及其应用 |
| ES2856457T3 (es) | 2015-02-05 | 2021-09-27 | Molecular Templates Inc | Moléculas de unión a CD20 multivalentes que comprenden regiones efectoras de una subunidad de toxina shiga y composiciones enriquecidas de estas |
| US10676723B2 (en) | 2015-05-11 | 2020-06-09 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| CN107849096B (zh) | 2015-05-30 | 2022-05-24 | 分子模板公司 | 去免疫化的志贺毒素a亚基支架和包含它们的细胞靶向分子 |
| US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| CN114773439A (zh) | 2016-12-07 | 2022-07-22 | 分子模板公司 | 用于位点特异性缀合的志贺毒素a亚基效应子多肽、志贺毒素效应子支架和细胞靶向分子 |
| MX2019008840A (es) | 2017-01-25 | 2019-09-09 | Molecular Templates Inc | Moleculas con direccion hacia las celulas que comprenden efectores de la sub-unidad a de la toxina shiga desinmunizados y epitopos de las celulas t cd8+. |
| AU2019257343A1 (en) | 2018-04-17 | 2020-09-10 | Molecular Templates, Inc. | HER2-targeting molecules comprising de-immunized, Shiga toxin A Subunit scaffolds |
| CN115856296B (zh) * | 2022-12-16 | 2023-07-25 | 华北理工大学 | 抗志贺氏菌的单克隆抗体及其检测中的应用 |
| CN120647752B (zh) * | 2025-08-19 | 2025-10-28 | 中国人民解放军军事科学院军事医学研究院 | 一种抗ⅱ型志贺毒素的单克隆抗体及其相关产品和应用 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5164298A (en) | 1988-06-24 | 1992-11-17 | Hsc Research Development Corporation | Verocytotoxin receptor assay |
| US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| AU669124B2 (en) | 1991-09-18 | 1996-05-30 | Kyowa Hakko Kirin Co., Ltd. | Process for producing humanized chimera antibody |
| US5552144A (en) * | 1992-01-22 | 1996-09-03 | Microcarb, Inc. | Immunogenic shiga-like toxin II variant mutants |
| US5747272A (en) | 1994-02-14 | 1998-05-05 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Detection of shiga-like toxins of enterohemoragic Escherichia coli |
| US5968894A (en) | 1994-02-22 | 1999-10-19 | Lingwood; Clifford A. | Verotoxin pharmaceutical compositions and medical treatments therewith |
| EP0929679A2 (en) | 1996-09-10 | 1999-07-21 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Histidine-tagged shiga toxins, toxoids, and protein fusions with such toxins and toxoids, methods for the purification and preparation thereof |
| WO1998020903A1 (en) | 1996-11-15 | 1998-05-22 | Trustees Of Tufts College | Humanized neutralizing antibodies against hemolytic uremic syndrome |
| US7910096B2 (en) | 1996-11-15 | 2011-03-22 | Trustees Of Tufts College | Human neutralizing antibodies against hemolytic uremic syndrome |
| US20020160005A1 (en) * | 1996-11-15 | 2002-10-31 | Trustees Of Tufts College | Human neutralizing antibodies against hemolytic urmec syndrome |
| US20030170248A1 (en) * | 1997-12-23 | 2003-09-11 | Jeffrey R. Stinson | Humanized monoclonal antibodies that protect against shiga toxin induced disease |
| IL139571A0 (en) | 1998-05-20 | 2002-02-10 | Teijin Ltd | A humanized antibody that binds to verotoxin, methods for the production thereof and pharmaceutical compositions containing the same |
| ATE504312T1 (de) * | 2003-07-21 | 2011-04-15 | Intervet Int Bv | Hybrid-toxine mit shiga-artigen toxin- untereinheiten, verbunden mit escherichia coli wärmeinstabilen enterotoxin-untereinheiten und vakzine daraus |
| AU2004293502B2 (en) | 2003-11-28 | 2010-12-02 | National Research Council Of Canada | Anticarcinoma antibodies and uses thereof |
| JP2008507253A (ja) | 2004-02-06 | 2008-03-13 | ナイモックス コーポレーション | ヒト化抗体 |
| CA2458084A1 (en) | 2004-03-12 | 2005-09-12 | Dalton Chemical Laboratories Inc. | Novel process for octreotide synthesis |
| WO2006091677A1 (en) * | 2005-02-22 | 2006-08-31 | Jean Gariepy | Yeast strains expressing ribosome-inactivating protein domain and method of using same |
| ES2532985T3 (es) | 2006-02-16 | 2015-04-06 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Proteínas quiméricas de toxoide de Shiga |
| MX2008013363A (es) | 2006-04-20 | 2009-03-26 | Jackson H M Found Military Med | Metodos y composiciones basados en la proteina tipo 1 de la toxina shiga. |
| JP2009538916A (ja) | 2006-05-31 | 2009-11-12 | タリオン ファーマシューティカルズ インコーポレーテッド | 志賀毒素関連病状を治療するための方法、組成物、およびキット |
| US20090258010A1 (en) | 2006-05-31 | 2009-10-15 | Thallion Pharmaceuticals, Inc. | Methods, compositions, and kits for treating shiga toxin associated conditions |
| AU2007339753A1 (en) * | 2006-12-29 | 2008-07-10 | Osprey Pharmaceuticals Usa, Inc. | Methods of selecting and producing modified toxins, conjugates containing modified toxins and uses thereof |
| US20100298238A1 (en) | 2007-10-08 | 2010-11-25 | Rutgers, The State University | Nontoxic shiga-like toxin mutant compositions and methods |
| CN101314616B (zh) * | 2008-05-30 | 2011-05-11 | 中国人民解放军第三军医大学 | 肠出血性大肠杆菌o157:h7志贺毒素ⅱb表位肽及其应用 |
| US20110165680A1 (en) * | 2008-09-12 | 2011-07-07 | Scarab Genomics, Llc | Clean genome bactofection |
| CA2748873C (en) | 2009-01-23 | 2017-09-12 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Methods and compositions based on shiga toxin type 2 protein |
-
2010
- 2010-01-21 CA CA2748873A patent/CA2748873C/en active Active
- 2010-01-21 CN CN2010800052595A patent/CN102292098A/zh active Pending
- 2010-01-21 AU AU2010206800A patent/AU2010206800B2/en active Active
- 2010-01-21 EP EP10733840.2A patent/EP2381954B8/en active Active
- 2010-01-21 PE PE2011001368A patent/PE20120425A1/es not_active Application Discontinuation
- 2010-01-21 RU RU2011126896/10A patent/RU2011126896A/ru not_active Application Discontinuation
- 2010-01-21 US US13/142,556 patent/US8969529B2/en active Active
- 2010-01-21 ES ES10733840.2T patent/ES2614803T3/es active Active
- 2010-01-21 JP JP2011548095A patent/JP5773886B2/ja active Active
- 2010-01-21 MX MX2011007866A patent/MX2011007866A/es unknown
- 2010-01-21 NZ NZ593926A patent/NZ593926A/xx not_active IP Right Cessation
- 2010-01-21 KR KR1020117019455A patent/KR101832499B1/ko not_active Expired - Fee Related
- 2010-01-21 WO PCT/US2010/021610 patent/WO2010085539A1/en not_active Ceased
- 2010-01-21 BR BRPI1007230-6A patent/BRPI1007230B1/pt not_active IP Right Cessation
- 2010-01-22 AR ARP100100141A patent/AR075047A1/es not_active Application Discontinuation
-
2011
- 2011-07-21 CL CL2011001769A patent/CL2011001769A1/es unknown
-
2015
- 2015-02-23 US US14/628,667 patent/US9801931B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JP5773886B2 (ja) | 2015-09-02 |
| BRPI1007230B1 (pt) | 2019-11-12 |
| EP2381954A1 (en) | 2011-11-02 |
| US8969529B2 (en) | 2015-03-03 |
| PE20120425A1 (es) | 2012-05-03 |
| EP2381954B1 (en) | 2016-11-02 |
| RU2011126896A (ru) | 2013-02-27 |
| EP2381954B8 (en) | 2017-01-25 |
| CA2748873A1 (en) | 2010-07-29 |
| AR075047A1 (es) | 2011-03-02 |
| US20160243210A1 (en) | 2016-08-25 |
| KR20110119725A (ko) | 2011-11-02 |
| WO2010085539A1 (en) | 2010-07-29 |
| KR101832499B1 (ko) | 2018-02-26 |
| CN102292098A (zh) | 2011-12-21 |
| CA2748873C (en) | 2017-09-12 |
| US20110318357A1 (en) | 2011-12-29 |
| MX2011007866A (es) | 2011-10-06 |
| BRPI1007230A2 (pt) | 2016-02-16 |
| NZ593926A (en) | 2013-03-28 |
| US9801931B2 (en) | 2017-10-31 |
| EP2381954A4 (en) | 2012-08-01 |
| AU2010206800A1 (en) | 2011-07-28 |
| AU2010206800B2 (en) | 2016-06-30 |
| CL2011001769A1 (es) | 2012-08-31 |
| JP2012515551A (ja) | 2012-07-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2614803T3 (es) | Métodos y composiciones basadas en proteína tipo 2 de la toxina Shiga | |
| US20130101591A1 (en) | Methods and compositions based on shiga toxin type 1 protein | |
| JPH06501382A (ja) | ライム病の予防および診断に用いる組成物および方法 | |
| Olsen et al. | A Chlamydia trachomatis VD1-MOMP vaccine elicits cross-neutralizing and protective antibodies against C/C-related complex serovars | |
| KR20100126760A (ko) | 클로스트리듐 디피실레 포자에 대한 항체 및 그 용도 | |
| Chourasia et al. | Delineation of immunodominant and cytadherence segment (s) of Mycoplasma pneumoniae P1 gene | |
| Haque et al. | Human B cell epitope map of the Lyme disease vaccine antigen, OspA | |
| EP3080160A1 (en) | Antibodies against staphylococcus aureus and uses thereof | |
| US20160075768A1 (en) | Adjuvant therapy for staphylococcal infection with enterotoxin specific mabs | |
| WO2019133799A1 (en) | Monoclonal antibodies targeting microtubule-binding domain of tau protein | |
| Davenport et al. | The variable C-terminal region of the Mycobacterium leprae 70-kilodalton heat shock protein is the target for humoral immune responses | |
| Bertoldi et al. | Exploiting chimeric human antibodies to characterize a protective epitope of Neisseria adhesin A, one of the Bexsero vaccine components | |
| Qiu et al. | Identification of B-cell epitopes in urease B subunit of Helicobacter pylori bound by neutralizing antibodies | |
| KR101905083B1 (ko) | 비브리오 콜레라균 엠에이알티엑스 브이씨(martxvc) 단백질에 교차 결합하는 단일클론항체 및 이의 용도 | |
| Imani et al. | Production and characterization of pertussis toxin specific monoclonal and polyclonal antibodies: Implication for toxin purification and detection | |
| KR101905095B1 (ko) | 비브리오 콜레라균 엠에이알티엑스 브이씨(martxvc) 단백질에 교차 결합하는 단일클론항체 및 이의 용도 | |
| Chourasia et al. | Delineation of immunodominant and | |
| Huang et al. | Prepared polyclonal antibody of the ciprofloxacin | |
| Nguyen et al. | The Structural Basis of Salmonella A 2 B 5 Neutralization by Antibodies Targeting the Glycan-Receptor Binding Subunits | |
| JPWO2014142356A1 (ja) | 強皮症治療剤 |